Skip to main content

Corcept Therapeutics Incorporat (CORT) Stock Analysis

Recovery setup

Buy WaitModerate Confidence

Healthcare · Biotechnology

Earnings in 0 days (2026-04-30). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Wait for pullback to $44.32. Weak momentum — blocks BUY_NOW at $46.66. Engine's entry $44.32 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Korlym; Concentration risk — Supplier: Curant (99.0%).

Corcept Therapeutics is a commercial-stage pharmaceutical company that markets Korlym (mifepristone) and its authorized generic for treatment of hypercortisolism (Cushing's syndrome) exclusively in the US. All revenue is dependent on these Products; the company also has pipeline... Read more

$46.66+29.2% A.UpsideScore 5.9/10#25 of 158 Biotechnology
Entry $44.32(Atr Pullback Sticky)Stop $41.18Target $58.64(analyst − 13%)A.R:R 1.8:1Setup A.R:R 4.2:1
Analyst target$67.40+44.4%5 analysts
$58.64our TP
$46.66price
$67.40mean
$110

Wait for pullback to $44.32. Weak momentum — blocks BUY_NOW at $46.66. Engine's entry $44.32 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Korlym; Concentration risk — Supplier: Curant (99.0%). Chart setup: Death cross but MACD improving, RSI 74. Earnings in 0 days. Wait until post-earnings. Score 5.9/10, moderate confidence.

Passes 5/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: moderate.

Val5.9Qual6.2Grw7.7Mom5.2Sent6.8Ins5.0Peer5.4Tech0.8Risk5.25.9OVERALL

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: Korlym
Concentration risk — Supplier: Curant (99.0%)

Key Metrics

P/E (TTM)56.8
P/E (Fwd)29.0
Mkt Cap$5.0B
EV/EBITDA99.9
Profit Mgn13.1%
ROE15.0%
Rev Growth11.1%
Beta0.25
DividendNone
Rating analysts12

Quality Signals

Piotroski F8/9

Options Flow

P/C1.33bearish
IV63%elevated
Max Pain$130+178.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductKorlym
    10-K Item 1A: 'The availability of generic versions of Korlym could adversely affect our business, results of operations and financial position'
  • HIGHSupplierCurant99%
    10-K Item 1A: 'Our new specialty pharmacy vendor, Curant, dispenses our Products...including the collection of payments from insurers representing more than 99 percent of our revenue'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
0.0
Support Resistance
0.5
Bollinger
1.8
GatesEARNINGS PROXIMITY 0d<=7dMomentum 5.2<5.5 (soft — BUY_NOW allowed but watch)Death cross (50MA < 200MA)Momentum 5.2>=4.5A.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
74 · Overbought
↑ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $40.36Resistance $47.29

Price Targets

$41
$44
$59
A.Upside+25.7%
A.R:R1.8:1
Setup A.R:R (at entry)4.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Earnings in 0 days - binary event risk
! EARNINGS_PROXIMITY:0d<=7d

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-04-30 (0d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CORT stock a buy right now?

Wait for pullback to $44.32. Weak momentum — blocks BUY_NOW at $46.66. Engine's entry $44.32 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: Korlym; Concentration risk — Supplier: Curant (99.0%). Chart setup: Death cross but MACD improving, RSI 74. Earnings in 0 days. Wait until post-earnings. Target $58.64 (+25.7%), stop $41.18 (−13.3%), Setup A.R:R 4.2:1. Score 5.9/10, moderate confidence.

What is the CORT stock price target?

Take-profit target: $58.64 (+29.2% upside). Target $58.64 (+25.7%), stop $41.18 (−13.3%), Setup A.R:R 4.2:1. Stop-loss: $41.18.

What are the risks of investing in CORT?

Concentration risk — Product: Korlym; Concentration risk — Supplier: Curant (99.0%).

Is CORT overvalued or undervalued?

Corcept Therapeutics Incorporat trades at a P/E of 56.8 (forward 29.0). TrendMatrix value score: 5.9/10. Verdict: Buy (Wait for Entry).

What do analysts say about CORT?

12 analysts cover CORT with a consensus score of 3.9/5. Average price target: $67.

What does Corcept Therapeutics Incorporat do?Corcept Therapeutics is a commercial-stage pharmaceutical company that markets Korlym (mifepristone) and its authorized...

Corcept Therapeutics is a commercial-stage pharmaceutical company that markets Korlym (mifepristone) and its authorized generic for treatment of hypercortisolism (Cushing's syndrome) exclusively in the US. All revenue is dependent on these Products; the company also has pipeline selective cortisol modulators in clinical trials for oncology, MASH, and ALS.

Related stocks: NVAX (Novavax, Inc.) · HRMY (Harmony Biosciences Holdings, I) · INCY (Incyte Corporation) · CPRX (Catalyst Pharmaceuticals, Inc.) · AUPH (Aurinia Pharmaceuticals Inc)